1
|
Misra S, Peters G, Barnes E, Ardern-Holmes S, Webster R, Troedson C, Mohammad SS, Gill D, Menezes M, Gupta S, Procopis P, Antony J, Kurian MA, Dale RC. Yield of comparative genomic hybridization microarray in pediatric neurology practice. NEUROLOGY-GENETICS 2019; 5:e367. [PMID: 31872051 PMCID: PMC6878849 DOI: 10.1212/nxg.0000000000000367] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 08/28/2019] [Indexed: 12/14/2022]
Abstract
Objective The present study investigated the diagnostic yield of array comparative genomic hybridization (aCGH) in a large cohort of children with diverse neurologic disorders as seen in child neurology practice to test whether pathogenic copy number variants (CNVs) were more likely to be detected in specific neurologic phenotypes. Methods A retrospective cross-sectional analysis was performed on 555 children in whom a genetic etiology was suspected and who underwent whole-genome aCGH testing between 2006 and 2012. Neurologic phenotyping was performed using hospital medical records. An assessment of pathogenicity was made for each CNV, based on recent developments in the literature. Results Forty-seven patients were found to carry a pathogenic CNV, giving an overall diagnostic yield of 8.59%. Certain phenotypes predicted for the presence of a pathogenic CNV, including developmental delay (odds ratio [OR] 3.69 [1.30-10.51]), cortical visual impairment (OR 2.73 [1.18-6.28]), dysmorphism (OR 2.75 [1.38-5.50]), and microcephaly (OR 2.16 [1.01-4.61]). The combination of developmental delay/intellectual disability with dysmorphism and abnormal head circumference was also predictive for a pathogenic CNV (OR 2.86 [1.02-8.00]). For every additional clinical feature, there was an increased likelihood of detecting a pathogenic CNV (OR 1.18 [1.01-1.38]). Conclusions The use of aCGH led to a pathogenic finding in 8.59% of patients. The results support the use of aCGH as a first tier investigation in children with diverse neurologic disorders, although whole-genome sequencing may replace aCGH as the detection method in the future. In particular, the yield was increased in children with developmental delay, dysmorphism, cortical visual impairment, and microcephaly.
Collapse
Affiliation(s)
- Shibalik Misra
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Greg Peters
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Elizabeth Barnes
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Simone Ardern-Holmes
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Richard Webster
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Christopher Troedson
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Shekeeb S Mohammad
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Deepak Gill
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Manoj Menezes
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Sachin Gupta
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Peter Procopis
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Jayne Antony
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Manju A Kurian
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| | - Russell C Dale
- Kids Neuroscience Centre (S.M., R.D.), the Children's Hospital at Westmead, Faculty of Medicine and Health, the University of Sydney; Department of Clinical Genetics (G.P.) at the Children's Hospital at Westmead; Kids Research Institute at Westmead (E.B.); TY Nelson Department of Neurology and Neurosurgery at the Children's Hospital at Westmead Sydney (S.A.-H., R.W., C.T., S.S.M., D.G., M.M., S.G., P.P., J.A., R.C.D.), New South Wales, Australia; and Institute of Child Health (M.K.), University College London, UK
| |
Collapse
|
2
|
Hnoonual A, Thammachote W, Tim-Aroon T, Rojnueangnit K, Hansakunachai T, Sombuntham T, Roongpraiwan R, Worachotekamjorn J, Chuthapisith J, Fucharoen S, Wattanasirichaigoon D, Ruangdaraganon N, Limprasert P, Jinawath N. Chromosomal microarray analysis in a cohort of underrepresented population identifies SERINC2 as a novel candidate gene for autism spectrum disorder. Sci Rep 2017; 7:12096. [PMID: 28935972 PMCID: PMC5608768 DOI: 10.1038/s41598-017-12317-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 09/07/2017] [Indexed: 01/11/2023] Open
Abstract
Chromosomal microarray (CMA) is now recognized as the first-tier genetic test for detection of copy number variations (CNVs) in patients with autism spectrum disorder (ASD). The aims of this study were to identify known and novel ASD associated-CNVs and to evaluate the diagnostic yield of CMA in Thai patients with ASD. The Infinium CytoSNP-850K BeadChip was used to detect CNVs in 114 Thai patients comprised of 68 retrospective ASD patients (group 1) with the use of CMA as a second line test and 46 prospective ASD and developmental delay patients (group 2) with the use of CMA as the first-tier test. We identified 7 (6.1%) pathogenic CNVs and 22 (19.3%) variants of uncertain clinical significance (VOUS). A total of 29 patients with pathogenic CNVs and VOUS were found in 22% (15/68) and 30.4% (14/46) of the patients in groups 1 and 2, respectively. The difference in detected CNV frequencies between the 2 groups was not statistically significant (Chi square = 1.02, df = 1, P = 0.31). In addition, we propose one novel ASD candidate gene, SERINC2, which warrants further investigation. Our findings provide supportive evidence that CMA studies using population-specific reference databases in underrepresented populations are useful for identification of novel candidate genes.
Collapse
Affiliation(s)
- Areerat Hnoonual
- Graduate Program in Biomedical Sciences, Prince of Songkla University, Songkhla, Thailand
| | - Weerin Thammachote
- Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Thipwimol Tim-Aroon
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Kitiwan Rojnueangnit
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine, Thammasart University, Pathumthani, Thailand
| | - Tippawan Hansakunachai
- Division of Child Development, Department of Pediatrics, Faculty of Medicine, Thammasart University, Pathumthani, Thailand
| | - Tasanawat Sombuntham
- Division of Developmental-Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Rawiwan Roongpraiwan
- Division of Developmental-Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Juthamas Worachotekamjorn
- Division of Child Development, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Jariya Chuthapisith
- Division of Developmental-Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Suthat Fucharoen
- Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand
| | - Duangrurdee Wattanasirichaigoon
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Nichara Ruangdaraganon
- Division of Developmental-Behavioral Pediatrics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Pornprot Limprasert
- Division of Human Genetics, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
| | - Natini Jinawath
- Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. .,Integrative Computational Bioscience Center, Mahidol University, Salaya, Nakhon Pathom, Thailand.
| |
Collapse
|
3
|
Kehrer M, Liehr T, Benkert T, Singer S, Grasshoff U, Schaeferhoff K, Bonin M, Weichselbaum A, Tzschach A. Interstitial duplication of chromosome region 1q25.1q25.3: report of a patient with mild cognitive deficits, tall stature and facial dysmorphisms. Am J Med Genet A 2016; 167A:653-6. [PMID: 25691419 DOI: 10.1002/ajmg.a.36943] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Accepted: 12/07/2014] [Indexed: 11/05/2022]
Abstract
Isolated interstitial duplications of chromosome band 1q25 are apparently very rare; no patients with detailed molecular and clinical characterization of duplications restricted to this region have been published to date. We report on a 9-year-old girl with mild cognitive deficits, tall stature, macrocephaly and discrete dysmorphic features in whom a de novo interstitial 7.5 Mb duplication of 1q25.1q25.3 was detected by SNP array analysis (arr[hg19] 1q25.1q25.3(173,925,505-181,381,242)x3 dn). The duplicated region was inversely inserted into chromosome band 1q42.2: 46,XX,der(1)(pter→q42.2::q25.3→q25.1::q42.2→qter). Overexpression of one or several of the 87 genes in the duplicated interval was presumably the major causative factor for the clinical manifestations. Reports of additional patients with overlapping duplications will be needed to establish detailed karyotype-phenotype correlations and to gain a better understanding of the underlying pathomechanisms.
Collapse
Affiliation(s)
- Martin Kehrer
- Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Microdeletions in 9q33.3-q34.11 in five patients with intellectual disability, microcephaly, and seizures of incomplete penetrance: is STXBP1 not the only causative gene? Mol Cytogenet 2015; 8:72. [PMID: 26421060 PMCID: PMC4587785 DOI: 10.1186/s13039-015-0178-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 09/22/2015] [Indexed: 11/18/2022] Open
Abstract
Background Most microdeletions involving chromosome sub-bands 9q33.3-9q34.11 to this point have been detected by analyses focused on STXBP1, a gene known to cause early infantile epileptic encephalopathy 4 and other seizure phenotypes. Loss-of-function mutations of STXBP1 have also been identified in some patients with intellectual disability without epilepsy. Consequently, STXBP1 is widely assumed to be the gene causing both seizures and intellectual disability in patients with 9q33.3-q34.11 microdeletions. Results We report five patients with overlapping microdeletions of chromosome 9q33.3-q34.11, four of them previously unreported. Their common clinical features include intellectual disability, psychomotor developmental delay with delayed or absent speech, muscular hypotonia, and strabismus. Microcephaly and short stature are each present in four of the patients. Two of the patients had seizures. De novo deletions range from 1.23 to 4.13 Mb, whereas the smallest deletion of 432 kb in patient 3 was inherited from her mother who is reported to have mild intellectual disability. The smallest region of overlap (SRO) of these deletions in 9q33.3 does not encompass STXBP1, but includes two genes that have not been previously associated with disease, RALGPS1 and GARNL3. Sequencing of the two SRO genes RALGPS1 and GARNL3 in at least 156 unrelated patients with mild to severe idiopathic intellectual disability detected no causative mutations. Gene expression analyses in our patients demonstrated significantly reduced expression levels of GARNL3, RALGPS1 and STXBP1 only in patients with deletions of the corresponding genes. Thus, reduced expression of STXBP1 was ruled out as a cause for seizures in our patient whose deletion did not encompass STXBP1. Conclusions We suggest that microdeletions of this region on chromosome 9q cause a clinical spectrum including intellectual disability, developmental delay especially concerning speech, microcephaly, short stature, mild dysmorphisms, strabismus, and seizures of incomplete penetrance, and may constitute a new contiguous gene deletion syndrome which cannot completely be explained by deletion of STXBP1. Electronic supplementary material The online version of this article (doi:10.1186/s13039-015-0178-8) contains supplementary material, which is available to authorized users.
Collapse
|
5
|
D'Amours G, Langlois M, Mathonnet G, Fetni R, Nizard S, Srour M, Tihy F, Phillips MS, Michaud JL, Lemyre E. SNP arrays: comparing diagnostic yields for four platforms in children with developmental delay. BMC Med Genomics 2014; 7:70. [PMID: 25539807 PMCID: PMC4299176 DOI: 10.1186/s12920-014-0070-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Accepted: 12/11/2014] [Indexed: 11/28/2022] Open
Abstract
Background Molecular karyotyping is now the first-tier genetic test for patients affected with unexplained intellectual disability (ID) and/or multiple congenital anomalies (MCA), since it identifies a pathogenic copy number variation (CNV) in 10-14% of them. High-resolution microarrays combining molecular karyotyping and single nucleotide polymorphism (SNP) genotyping were recently introduced to the market. In addition to identifying CNVs, these platforms detect loss of heterozygosity (LOH), which can indicate the presence of a homozygous mutation or uniparental disomy. Since these abnormalities can be associated with ID and/or MCA, their detection is of particular interest for patients whose phenotype remains unexplained. However, the diagnostic yield obtained with these platforms is not confirmed, and the real clinical value of LOH detection has not been established. Methods We selected 21 children affected with ID, with or without congenital malformations, for whom standard genetic analyses failed to provide a diagnosis. We performed high-resolution SNP array analysis with four platforms (Affymetrix Genome-Wide Human SNP Array 6.0, Affymetrix Cytogenetics Whole-Genome 2.7 M array, Illumina HumanOmni1-Quad BeadChip, and Illumina HumanCytoSNP-12 DNA Analysis BeadChip) on whole-blood samples obtained from children and their parents to detect pathogenic CNVs and LOHs, and compared the results with those obtained on a moderate resolution array-based comparative genomic hybridization platform (NimbleGen CGX-12 Cytogenetics Array), already used in the clinical setting. Results We identified a total of four pathogenic CNVs in three patients, and all arrays successfully detected them. With the SNP arrays, we also identified a LOH containing a gene associated with a recessive disorder consistent with the patient’s phenotype (i.e., an informative LOH) in four children (including two siblings). A homozygous mutation within the informative LOH was found in three of these patients. Therefore, we were able to increase the diagnostic yield from 14.3% to 28.6% as a result of the information provided by LOHs. Conclusions This study shows the clinical usefulness of SNP arrays in children with ID, since they successfully detect pathogenic CNVs, identify informative LOHs that can lead to the diagnosis of a recessive disorder. It also highlights some challenges associated with the use of SNP arrays in a clinical laboratory. Electronic supplementary material The online version of this article (doi:10.1186/s12920-014-0070-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Guylaine D'Amours
- Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada.
| | - Mathieu Langlois
- Centre de pharmacogénomique, Institut de cardiologie de Montréal, Montréal, QC, Canada.
| | | | - Raouf Fetni
- Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada. .,Département de pathologie, CHU Sainte-Justine, Montréal, QC, Canada. .,Pathologie et biologie cellulaire, Université de Montréal, Montréal, QC, Canada.
| | - Sonia Nizard
- Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada. .,Pédiatrie, Université de Montréal, Montréal, QC, Canada.
| | - Myriam Srour
- Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada.
| | - Frédérique Tihy
- Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada. .,Pathologie et biologie cellulaire, Université de Montréal, Montréal, QC, Canada.
| | - Michael S Phillips
- Centre de pharmacogénomique, Institut de cardiologie de Montréal, Montréal, QC, Canada.
| | - Jacques L Michaud
- Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada. .,Pédiatrie, Université de Montréal, Montréal, QC, Canada.
| | - Emmanuelle Lemyre
- Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada. .,Faculté de médecine, Université de Montréal, Montréal, QC, Canada. .,Pédiatrie, Université de Montréal, Montréal, QC, Canada.
| |
Collapse
|
6
|
Vulto-van Silfhout AT, Hehir-Kwa JY, van Bon BWM, Schuurs-Hoeijmakers JHM, Meader S, Hellebrekers CJM, Thoonen IJM, de Brouwer APM, Brunner HG, Webber C, Pfundt R, de Leeuw N, de Vries BBA. Clinical significance of de novo and inherited copy-number variation. Hum Mutat 2013; 34:1679-87. [PMID: 24038936 DOI: 10.1002/humu.22442] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Accepted: 08/30/2013] [Indexed: 12/22/2022]
Abstract
Copy-number variations (CNVs) are a common cause of intellectual disability and/or multiple congenital anomalies (ID/MCA). However, the clinical interpretation of CNVs remains challenging, especially for inherited CNVs. Well-phenotyped patients (5,531) with ID/MCA were screened for rare CNVs using a 250K single-nucleotide polymorphism array platform in order to improve the understanding of the contribution of CNVs to a patients phenotype. We detected 1,663 rare CNVs in 1,388 patients (25.1%; range 0-5 per patient) of which 437 occurred de novo and 638 were inherited. The detected CNVs were analyzed for various characteristics, gene content, and genotype-phenotype correlations. Patients with severe phenotypes, including organ malformations, had more de novo CNVs (P < 0.001), whereas patient groups with milder phenotypes, such as facial dysmorphisms, were enriched for both de novo and inherited CNVs (P < 0.001), indicating that not only de novo but also inherited CNVs can be associated with a clinically relevant phenotype. Moreover, patients with multiple CNVs presented with a more severe phenotype than patients with a single CNV (P < 0.001), pointing to a combinatorial effect of the additional CNVs. In addition, we identified 20 de novo single-gene CNVs that directly indicate novel genes for ID/MCA, including ZFHX4, ANKH, DLG2, MPP7, CEP89, TRIO, ASTN2, and PIK3C3.
Collapse
Affiliation(s)
- Anneke T Vulto-van Silfhout
- Department of Human Genetics, Nijmegen Centre for Molecular Life Sciences and Institute for Genetic and Metabolic Disorders, Radboud University Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Filges I, Kang A, Klug V, Wenzel F, Heinimann K, Tercanli S, Miny P. Array comparative genomic hybridization in prenatal diagnosis of first trimester pregnancies at high risk for chromosomal anomalies. Mol Cytogenet 2012; 5:38. [PMID: 22979998 PMCID: PMC3462716 DOI: 10.1186/1755-8166-5-38] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Accepted: 07/30/2012] [Indexed: 01/14/2023] Open
Abstract
Objective To describe the diagnostic performance of array comparative genomic hybridization (aCGH) as a potential first line diagnostic method in first trimester high risk pregnancies. Method In a retrospective study we performed aCGH using a targeted array BAC platform (Constitutional Chip® 4.0, PerkinElmer, Turku Finland, median resolution 600 kB) and the Affymetrix Cytogenetics® Whole Genome 2.7 M array (at a resolution of 400kB) on 100 anonymized prenatal samples from first trimester high risk pregnancies with normal conventional karyotype. We studied the technical feasibility and turn-around-time as well as the detection rate of pathogenic submicroscopic chromosome anomalies and CNVs of unknown significance. Results We obtained results in 98 of 100 samples in 3 to a maximum of 5 days after DNA extraction. At the given resolution we did not identify any additional pathogenic CNVs but two CNVs of unknown significance in the chromosomal regions 1q21.1q21.2 (deletion) and 5p15.33 (duplication) (2%). Conclusion In accordance with a growing number of reports this study supports the concept that aCGH at a resolution of 400-600kB may be used as a first line prenatal diagnostic test with high diagnostic safety and rapid turn-around time in high-risk first trimester pregnancies. Detection rate of CNVs of unknown significance, considered as a major hindrance for replacing conventional karyotyping by aCGH, is 2%, but the diagnosis of additional submicroscopic anomalies in this heterogeneous group of patients seems to be rare.
Collapse
Affiliation(s)
- Isabel Filges
- Dr, med, Isabel Filges, Division of Medical Genetics, University Children's Hospital and Department of Biomedicine, University of Basel, Burgfelderstrasse 101, Building J, CH-4055, Basel, Switzerland.
| | | | | | | | | | | | | |
Collapse
|